FTM
First Turn Management Portfolio holdings
AUM
$536M
This Quarter Return
-0.83%
1 Year Return
+36.36%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$558M
AUM Growth
+$558M
(-12%)
Cap. Flow
-$41.8M
Cap. Flow
% of AUM
-7.48%
Top 10 Holdings %
Top 10 Hldgs %
44.81%
Holding
45
New
7
Increased
11
Reduced
13
Closed
9
Top Buys
| 1 |
Janux Therapeutics
JANX
|
$20.5M |
| 2 |
Revolution Medicines
RVMD
|
$17.7M |
| 3 |
Exact Sciences
EXAS
|
$17.4M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$14.1M |
| 5 |
HealthEquity
HQY
|
$12.1M |
Top Sells
| 1 |
Transmedics
TMDX
|
$17.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$16.4M |
| 3 |
Establishment Labs
ESTA
|
$15.4M |
| 4 |
Repligen
RGEN
|
$13.2M |
| 5 |
Krystal Biotech
KRYS
|
$12.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $30.9M | 5.53% |
446,980
+90,529
| +25% | +$6.25M |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $29.8M | 5.34% |
641,901
+68,973
| +12% | +$3.2M |
|
|
3
Xenon Pharmaceuticals
XENE
$2.98B
| $26.9M | 4.81% |
684,986
+359,768
| +111% | +$14.1M |
|
4
argenx
ARGX
$43.6B
| $26.5M | 4.75% |
43,078
-11,362
| -21% | -$6.99M |
|
|
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $24.6M | 4.4% |
294,414
+39,614
| +16% | +$3.31M |
|
6
Nuvalent
NUVL
$5.52B
| $24.2M | 4.34% |
309,521
-49,593
| -14% | -$3.88M |
|
7
Crinetics Pharmaceuticals
CRNX
$2.92B
| $23.2M | 4.15% |
453,376
+100,000
| +28% | +$5.11M |
|
8
Vaxcyte
PCVX
$4B
| $22.7M | 4.06% |
276,905
+64,920
| +31% | +$5.31M |
|
9
Mirum Pharmaceuticals
MIRM
$3.71B
| $21M | 3.75% |
506,908
-140,703
| -22% | -$5.82M |
|
|
10
Janux Therapeutics
JANX
$1.37B
| $20.5M | 3.68% |
+383,602
| New | +$20.5M |
|
11
Vera Therapeutics
VERA
$1.38B
| $19.7M | 3.52% |
464,807
+138,313
| +42% | +$5.85M |
|
12
Intuitive Surgical
ISRG
$170B
| $18.3M | 3.28% |
35,032
+4,778
| +16% | +$2.49M |
|
|
13
Revolution Medicines
RVMD
$7.1B
| $17.7M | 3.16% |
+403,915
| New | +$17.7M |
|
|
14
Exact Sciences
EXAS
$8.98B
| $17.4M | 3.12% |
+309,890
| New | +$17.4M |
|
15
Axsome Therapeutics
AXSM
$6.05B
| $16.3M | 2.91% |
192,146
-63,148
| -25% | -$5.34M |
|
16
Natera
NTRA
$23.1B
| $15.7M | 2.81% |
99,159
-56,491
| -36% | -$8.94M |
|
17
Glaukos
GKOS
$5.5B
| $14.4M | 2.58% |
96,097
| – | – |
|
18
Geron
GERN
$893M
| $13.8M | 2.47% |
3,893,327
+768,360
| +25% | +$2.72M |
|
19
BridgeBio Pharma
BBIO
$9.89B
| $12.4M | 2.22% |
452,290
+52,509
| +13% | +$1.44M |
|
20
Ascendis Pharma
ASND
$11.8B
| $12.1M | 2.17% |
87,804
-62,789
| -42% | -$8.64M |
|
|
21
HealthEquity
HQY
$7.72B
| $12.1M | 2.16% |
+125,867
| New | +$12.1M |
|
22
Enliven Therapeutics
ELVN
$1.2B
| $12M | 2.16% |
535,092
| – | – |
|
23
Day One Biopharmaceuticals
DAWN
$769M
| $12M | 2.15% |
947,878
| – | – |
|
24
Merus
MRUS
$4.98B
| $12M | 2.15% |
285,159
-22,855
| -7% | -$961K |
|
25
ADMA Biologics
ADMA
$4.12B
| $11.7M | 2.1% |
684,230
+19,245
| +3% | +$330K |
|